Bio-Rad Laboratories (BIO) Stock Price, News & Analysis

Company Overview

Bio-Rad Laboratories, Inc. is a global provider of life science research and clinical diagnostic products. The company operates through two primary business segments: Life Science and Clinical Diagnostics. Within the Life Science segment, Bio-Rad offers instruments, reagents and consumables for protein analysis, cell biology, gene expression and other molecular biology applications. The Clinical Diagnostics segment supplies quality control products, blood-typing reagents and instruments, and molecular diagnostic assays used in blood screening, infectious disease testing and routine clinical laboratories.

Founded in 1952 by David and Alice Schwartz and headquartered in Hercules, California, Bio-Rad has grown its footprint across the Americas, Europe, Asia-Pacific and other regions. Its life science tools support academic and pharmaceutical research, while its diagnostics solutions serve hospitals, reference laboratories and blood banks worldwide. The company places particular emphasis on product reliability, regulatory compliance and technical support for its diverse customer base.

Over its history, Bio-Rad has expanded through both internal development and strategic acquisitions, broadening its portfolio with products such as electrophoresis systems, imaging platforms, droplet digital PCR and automated blood-typing instruments. The firm is led by Norman Schwartz, who serves as chairman and chief executive officer, building on the legacy of its founders. Through continued investment in research and development, Bio-Rad aims to deliver innovative technologies that address evolving challenges in life science research and clinical diagnostics.

Key Stats

• Today's Range: $329.60 to $352.63
• 50-Day Range: $271.10 to $335.25
• 52-Week Range: $236.73 to $352.63
• Volume: 522,113 shs
• Average Volume: 330,742 shs
• Market Capitalization: $9.33 billion
• P/E Ratio: 57.41
• Dividend Yield: N/A
• Price Target: $343.33
• Consensus Rating: Reduce

Bio-Rad Laboratories Stock Analysis - MarketRank™

Bio-Rad Laboratories scored higher than 25% of companies evaluated by MarketBeat, and ranked 802nd out of 900 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 1.7 / 5
• Analyst Rating: Reduce

Consensus Rating

Bio-Rad Laboratories has received a consensus rating of Reduce. The company's average rating score is 1.80, and is based on no strong buy ratings, 1 buy rating, 2 hold ratings, and 2 sell ratings.

Upside/Downside

The consensus price target for Bio-Rad Laboratories is close to its current price, suggesting limited near-term upside or downside.

Amount of Analyst Coverage

Bio-Rad Laboratories has only been the subject of 4 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: -1.20%

Earnings Growth

Earnings for Bio-Rad Laboratories are expected to decrease by -1.20% in the coming year, from $9.14 to $9.03 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Bio-Rad Laboratories is 56.85, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 40.46.

Price to Earnings Ratio vs. Sector

The P/E ratio of Bio-Rad Laboratories is 56.85, which means that it is trading at a less expensive P/E ratio than the Healthcare sector average P/E ratio of about 280.55.

Price to Book Value per Share Ratio

Bio-Rad Laboratories has a P/B Ratio of 1.25. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 1.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

8.37% of the float of Bio-Rad Laboratories has been sold short.

Short Interest Ratio / Days to Cover

Bio-Rad Laboratories has a short interest ratio ("days to cover") of 5.96.

Change versus previous month

Short interest in Bio-Rad Laboratories has recently increased by 2.79%, indicating that investor sentiment is decreasing.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Bio-Rad Laboratories does not currently pay a dividend.

Dividend Growth

Bio-Rad Laboratories does not have a long track record of dividend growth.

News and Social Media

• Score: 3.7 / 5
• News Sentiment: 0.87

News Sentiment

Bio-Rad Laboratories has a news sentiment score of 0.87. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.64 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 17 news articles for Bio-Rad Laboratories this week, compared to 2 articles on an average week.

Search Interest

4 people have searched for BIO on MarketBeat in the last 30 days.

Company Ownership

• Score: 1.4 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Bio-Rad Laboratories insiders have not sold or bought any company stock.

Percentage Held by Insiders

30.34% of the stock of Bio-Rad Laboratories is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

65.24% of the stock of Bio-Rad Laboratories is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 8/04/2026
• Today: 8/05/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NYSE
• Sector: Healthcare
• Industry: Life Sciences Tools & Services
• Sub-Industry: Life Sciences Tools & Services
• Current Symbol: NYSE:BIO
• CIK: 12208
• Web: www.bio-rad.com
• Phone: (510) 724-7000
• Fax: 510-741-5817
• Employees: 7,450
• Year Founded: 1952

Price Target and Rating

• Average Price Target for Bio-Rad Laboratories: $343.33
• High Price Target: $370.00
• Low Price Target: $330.00
• Potential Upside/Downside: -1.5%
• Consensus Rating: Reduce
• Rating Score (0-4): 1.80
• Research Coverage: 5 Analysts

Profitability

• EPS (Trailing Twelve Months): $6.07
• Trailing P/E Ratio: 57.41
• Forward P/E Ratio: 38.13
• P/E Growth: N/A
• Net Income: $759.90 million
• Net Margins: 6.52%
• Pretax Margin: 8.58%
• Return on Equity: 3.56%
• Return on Assets: 2.49%

Debt

• Debt-to-Equity Ratio: 0.12
• Current Ratio: 3.21
• Quick Ratio: 2.37

Sales & Book Value

• Annual Sales: $2.58 billion
• Price / Sales: 3.61
• Cash Flow: $10.43 per share
• Price / Cash Flow: 33.40
• Book Value: $276.16 per share
• Price / Book: 1.26

Miscellaneous

• Outstanding Shares: 26,760,000
• Free Float: 18,642,000
• Market Cap: $9.33 billion
• Optionable: Optionable
• Beta: 1.06